NEW YORK (GenomeWeb News) – Hologic said on Thursday that Canadian regulators approved two of the company's assays for the detection of high-risk strains of human papillomavirus.

Health Canada granted medical device licenses to Hologic's Aptima HPV and Aptima HPV 16 18/45 genotype assays. Both assays are in vitro nucleic acid amplification tests for detecting HPV strains that are associated with cervical cancer and precancerous lesions, Hologic said. The assays were approved to run on the company's Tigris instrument.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.

Aug
20
Sponsored by
Canon BioMedical

This webinar will provide an overview of recent advances in single-cell RNA sequencing from the perspectives of three research organizations.

Aug
27
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep
18
Sponsored by
Horizon Discovery

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.